Souhaitez-vous accéder aux communiqués récents ?

Company announcement – No. 11 / 2020 Zealand Pharma completes subscription of New Ordinary Shares and registration of capital increase Copenhagen, March 31, 2020 – In reference to Zealand Pharma A/S...

Company announcement – No. 09 / 2020 Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 137,236,000 A total of 741,816 new shares (the...

Company announcement – No. 08 / 2020 Annual General Meeting of Zealand Pharma A/S: Measures in consequence of COVID-19 Copenhagen, March 24, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...

Company announcement – No. 07 / 2020 Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim Zealand Pharma regains the worldwide rights to the Amylin analog...

Company announcement – No. 06 / 2020 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 05 / 2020 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, March 20, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ:...

Company Announcement – No. 04 / 2020 Zealand Pharma convenes its Annual General Meeting 2020 Copenhagen, March 11, 2020 – Zealand Pharma A/S ("Zealand") convenes the Company’s ordinary Annual...

Company announcement – No. 03 / 2020 Zealand Pharma advances pipeline and maintains strong cash position: full year results for 2019 Copenhagen, March 11, 2020 – Zealand Pharma A/S (“Zealand”)...

Press Release – No. 02 / 2020 Zealand Pharma hosts conference call on March 12 at 4 pm CET (11 am EDT) to present full year results for 2019 Copenhagen, February 26, 2020; updated March 9, 2020 –...

Press release – No. 03 / 2020 Zealand Pharma to attend Credit Suisse 2020 Global Healthcare Conference Copenhagen, February 27, 2020 – Executive Vice President, Research & Development and...